- Home
- WSBCP vs EXEL Comparison
WSBCP vs EXEL Comparison
Compare WSBCP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBCP
- EXEL
- Stock Information
- Founded
- WSBCP N/A
- EXEL 1994
- Country
- WSBCP United States
- EXEL United States
- Employees
- WSBCP 2195
- EXEL N/A
- Industry
- WSBCP Major Banks
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSBCP Finance
- EXEL Health Care
- Exchange
- WSBCP Nasdaq
- EXEL Nasdaq
- Market Cap
- WSBCP N/A
- EXEL 12.0B
- IPO Year
- WSBCP N/A
- EXEL 2000
- Fundamental
- Price
- WSBCP $25.43
- EXEL $45.55
- Analyst Decision
- WSBCP
- EXEL Buy
- Analyst Count
- WSBCP 0
- EXEL 18
- Target Price
- WSBCP N/A
- EXEL $43.65
- AVG Volume (30 Days)
- WSBCP N/A
- EXEL 3.7M
- Earning Date
- WSBCP N/A
- EXEL 08-05-2025
- Dividend Yield
- WSBCP N/A
- EXEL N/A
- EPS Growth
- WSBCP N/A
- EXEL 237.58
- EPS
- WSBCP N/A
- EXEL 2.20
- Revenue
- WSBCP N/A
- EXEL $2,298,922,000.00
- Revenue This Year
- WSBCP N/A
- EXEL $9.37
- Revenue Next Year
- WSBCP N/A
- EXEL $11.05
- P/E Ratio
- WSBCP N/A
- EXEL $20.36
- Revenue Growth
- WSBCP N/A
- EXEL 24.49
- 52 Week Low
- WSBCP N/A
- EXEL $22.13
- 52 Week High
- WSBCP N/A
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- WSBCP 69.65
- EXEL 56.79
- Support Level
- WSBCP $25.28
- EXEL $43.21
- Resistance Level
- WSBCP $25.24
- EXEL $48.74
- Average True Range (ATR)
- WSBCP 0.04
- EXEL 2.01
- MACD
- WSBCP 0.02
- EXEL 0.05
- Stochastic Oscillator
- WSBCP 100.00
- EXEL 31.61
About WSBCP WesBanco Inc. Depositary Shares Each Representing a 1/40th Interest in a Share of 6.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series A
Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.